OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. 

National Institute of Diabetes and Digestive and Kidney Diseases

OrsoBio

Thanks to Brian K. Buntz and Drug Discovery & Development for highlighting our programs and complementarity to #glp1 receptor agonists. https://lnkd.in/gBBEVvrd


At AASLD’s #tlm23 this weekend, OrsoBio collaborators Yasmine Liu, Ph.D., Prof. Johan Auwerx, and Takanori Takebe  presented beautiful data showing the benefits of ACMSD inhibition with TLC-065 to increase hepatic NAD+, reduce inflammation and fibrosis, and enhance mitochondrial function in mouse hepatocytes, a diet-induced thermoneutrality mouse model of NASH, and in iPSC-derived human liver organoids from NASH patients. These data support the potential of ACMSD inhibition to improve liver disease due to #NASH and other etiologies.

Read more here: https://lnkd.in/gq7-zvcr

OrsoBio roars with $60m to treat metabolic disorders

Company targets metabolism with therapies to restore energy stability and prevent organ dysfunction.

#longevity #investment #obesity

Today OrsoBio announced a $60M Series A financing to support advancement of our metabolic portfolio for the treatment of obesity and related disorders. We're thrilled to welcome our new investors, Longitude Capital, Enavate Sciences, and Eli Lilly and Company, and for the continued support from our existing investors, Samsara BioCapital and NuevaBio, as we embark on the next stage of our journey. 

Read the announcement here: https://lnkd.in/gEBDii36

We're excited to present Phase 1 data for our liver-targeted LXR inverse agonist, TLC-2716, at #AHA23 this week. The data demonstrate dose-dependent improvements in atherogenic lipids (e.g., TGs, LDL-C, LDL particles, apoB) and support Phase 2 development in severe hypertriglyceridemia and #NASH. Read more here: https://bwnews.pr/3sweuii 

Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system.

Apellis

Enzyvant is a biotechnology company dedicated to developing and commercializing transformative therapies for patients with rare diseases.

Enzyvant

Travere Therapeutics is a biopharmaceutical company focused on identifying, developing, and delivering life-changing therapies to people living with rare diseases.

Travere Therapeutics

Shionogi is a Japanese pharmaceutical company that focuses on research, development, manufacturing, and marketing of pharmaceuticals.

Shionogi

Phenex Pharmaceuticals is a biotechnology company specializing in the development of small molecule therapeutics for the treatment of liver diseases and viral infections.

Phenex Pharmaceuticals

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company that engages in the research, development, manufacturing, and marketing of pharmaceutical products.

Astellas

Orso Bio is a biotechnology company that specializes in developing and commercializing novel therapies for rare diseases. The company leverages its proprietary technology platform to discover and advance treatments that address unmet medical needs.

Orso Bio

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	May 15, 2024 11:53 AM	23165837
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 15, 2024 11:53 AM	d47c026e
translate crunchbase fundingrounds	general
peers	general
news basic	general
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:ORSOBIO

Orso Bio